Low molecular weight bioregulator of bacterial origin in condylomatosis therapy optimization

Condylomatosis is a disease characterized by the formation on the surface epithelium of the skin and mucous outgrowths, which can reach significant sizes. The cause of the disease is DNA-containing human papillomavirus (HPV), which have a high affinity for epithelial tissues of the genital organs, esophagus, anal canal and respiratory tract. Clinicians have described various patterns of use of the drug Liсopid in the treatment of condylomatosis. Of interest is the development and further implementation of condylomatosis therapy using a drug based on glucosaminyl muramyl dipeptide in order to correct immunodeficiency states and treat papillomavirus infection. Clinical condylomatosis of the external genitalia is presented. In the study of PCR on HPV, 33 types with a high viral load were detected. Diagnosis: Papillomavirus infection. Condylomas of the external genitalia. The goals of therapy and the treatment regimen: prescribing the drug Liсopid (AO Peptek, Moscow) to activate innate immunity, which allows to get an adequately high immune response at the level of both cellular and humoral local immunity. After the therapy, condylomas of the external genital organs were not found at the examination. The patient notes an improvement, the disappearance of itching. Thus, condylomatosis therapy according to the standard 10 mg Liсopid regimen for 10 days was effective, it contributed to the disappearance of genital warts, the clinical effect persisted for the entire observation period - 3 months. The clinical effectiveness of the drug can be explained by its systemic effect on the correction of immunity through NOD2 receptors.